Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

LDL-C lowering

  • Home
  • LDL-C lowering
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial
Posted inCardiology news

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

Posted by MedXY By MedXY 05/19/2026
In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary intervention.
Read More
Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial
Posted inCardiology Clinical Updates Diabetes & Endocrinology news Specialties

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

Posted by MedXY By MedXY 08/24/2025
The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.
Read More
  • Checkpoint Inhibition Is Reshaping Pediatric Lymphoma Care, Led by Breakthroughs in Hodgkin Lymphoma and Expanding into PD-L1–Positive Non-Hodgkin Subtypes
  • Loss of the Fibrinogen αC Region, Rather Than Hypofibrinogenemia Alone, Attenuates Experimental Arterial Thrombosis
  • A Chest X-Ray AI Age Gap May Flag Early Spirometric Decline Before Overt Lung Disease
  • Negative End-Expiratory Transpulmonary Pressure, Lung Collapse, and Non-Focal ARDS Drive Tidal Recruitment During Pressure Support Ventilation
  • Most Open-Angle Glaucoma Suspects Convert at Less Than 6% Per Year After Year 1, Supporting Risk-Stratified Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in